Share Price and Basic Stock Data
Last Updated: December 8, 2025, 4:47 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Genesis IBRC India Ltd operates in the seeds, tissue culture, and biotechnology sector, a niche that has shown promise in recent years. However, the company has faced significant challenges in generating consistent revenue. As per the latest reports, Genesis has not recorded any sales from June 2022 through March 2024, with a notable exception in September 2024 when it reported ₹3.67 lakh. This sporadic revenue generation raises questions about the company’s operational viability and market demand for its products. The historical sales figures reflect a rather erratic revenue trend, with total sales of merely ₹0.39 Cr in FY 2014, peaking at ₹0.78 Cr in FY 2015, before declining to zero over subsequent years. The current lack of sustained revenue poses a serious concern for potential investors, necessitating a closer look at the underlying business model and product offerings.
Profitability and Efficiency Metrics
When evaluating Genesis IBRC’s profitability, the figures present a mixed narrative. The company recorded a net profit of ₹3.48 Cr for the trailing twelve months, which may seem encouraging at first glance. However, this profit arises from an exceptional spike in September 2024, contrasting sharply with previous quarters where losses were commonplace. For instance, the operating profit margin (OPM) reached an impressive 99.46% in September 2024, but this is not indicative of consistent operational efficiency, given the preceding losses. The return on equity (ROE) and return on capital employed (ROCE) both stood at a remarkable 51.6%, suggesting effective use of capital when profits are realized. Yet, the reality of fluctuating profits, combined with a history of negative performance, hints at volatility that could be unsettling for risk-averse investors.
Balance Sheet Strength and Financial Ratios
From a balance sheet perspective, Genesis IBRC appears reasonably stable, with zero borrowings reported, which is a significant advantage. The company’s reserves, however, have been negative, standing at ₹-4.65 Cr, indicating that liabilities exceed assets. This negative reserve situation could pose risks to financial health, particularly if the company continues to experience operational challenges. The price-to-book value (P/BV) ratio of 0.71x suggests that the stock is trading below its book value, which may present an attractive entry point for value investors. Additionally, the interest coverage ratio (ICR) is recorded at 6.83x, indicating that the company can comfortably meet its interest obligations, though it currently has no interest-bearing debt. Overall, while the balance sheet shows no immediate liquidity concerns, the negative reserves warrant caution.
Shareholding Pattern and Investor Confidence
The shareholding structure of Genesis IBRC reveals a significant public stake of 88.68%, while promoters hold a modest 11.33%. This distribution may suggest a lack of strong insider confidence, which could be a red flag for potential investors. With 1,736 shareholders recorded, the investor base is relatively small but stable. The consistent promoter holding over time reflects a degree of commitment, albeit minimal, which may not be sufficient to instill confidence in the market. The absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) further complicates the picture, as institutional backing often adds a layer of credibility to a stock. This lack of institutional interest could be interpreted as a warning signal, underscoring the need for retail investors to conduct thorough due diligence.
Outlook, Risks, and Final Insight
Looking ahead, Genesis IBRC faces a challenging road. The sporadic revenue generation and historical losses paint a picture of volatility that could deter potential investors. While the recent profit figures might suggest a turnaround, they are not backed by consistent operational performance, raising questions about sustainability. The company’s reliance on a single quarter of profit may not be a solid foundation for future growth. Risks include the potential for further operational setbacks and the ongoing negative reserves, which could limit growth opportunities. Investors may want to approach Genesis IBRC with caution, weighing the potential for recovery against the backdrop of its unpredictable performance history. Understanding the complete business model and market positioning will be essential for making informed investment decisions in this high-risk environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genesis IBRC India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 7.89 Cr. | 25.8 | 100/23.1 | 78.8 | 12.8 | 0.00 % | 11.8 % | 9.68 % | 10.0 |
| Genesis IBRC India Ltd | 137 Cr. | 106 | 185/16.6 | 6.42 | 0.00 % | 51.6 % | 51.6 % | 10.0 | |
| Shreeoswal Seeds & Chemicals Ltd | 121 Cr. | 13.2 | 22.8/10.7 | 12.1 | 5.23 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 271 Cr. | 143 | 239/138 | 5.75 | 362 | 1.40 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 24.7 Cr. | 22.4 | 43.0/19.3 | 32.1 | 27.0 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 176.33 Cr | 62.08 | 32.19 | 82.69 | 0.28% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.05 | 0.01 | 0.02 | 0.05 | 0.06 | 0.02 | 0.02 | 3.69 | 0.10 | 0.02 | 0.03 | 0.02 | 0.12 |
| Operating Profit | -0.05 | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 |
| OPM % | 99.46% | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.05 | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 |
| EPS in Rs | -0.04 | -0.01 | -0.02 | -0.04 | -0.05 | -0.02 | -0.02 | -2.84 | -0.08 | 2.81 | -0.02 | -0.02 | -0.09 |
Last Updated: August 19, 2025, 2:45 pm
Below is a detailed analysis of the quarterly data for Genesis IBRC India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Mar 2025) to 0.12 Cr., marking an increase of 0.10 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.12 Cr.. The value appears to be declining and may need further review. It has decreased from -0.02 Cr. (Mar 2025) to -0.12 Cr., marking a decrease of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.12 Cr.. The value appears to be declining and may need further review. It has decreased from -0.02 Cr. (Mar 2025) to -0.12 Cr., marking a decrease of 0.10 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is -0.12 Cr.. The value appears to be declining and may need further review. It has decreased from -0.02 Cr. (Mar 2025) to -0.12 Cr., marking a decrease of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.09. The value appears to be declining and may need further review. It has decreased from -0.02 (Mar 2025) to -0.09, marking a decrease of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:16 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.39 | 0.78 | 0.00 | 0.00 | 0.29 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 |
| Expenses | 0.55 | 0.93 | 0.07 | 0.07 | 0.49 | 0.10 | 0.10 | 0.12 | 0.12 | 0.14 | 3.80 | 0.17 | 0.19 |
| Operating Profit | -0.16 | -0.15 | -0.07 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 | 3.48 |
| OPM % | -41.03% | -19.23% | -68.97% | -100.00% | 95.37% | 94.82% | |||||||
| Other Income | 0.01 | -0.09 | 0.42 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.18 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.33 | -0.45 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | 3.48 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.33 | -0.44 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | 3.48 |
| EPS in Rs | -1.09 | -0.62 | 0.36 | 0.00 | -0.15 | -0.04 | -0.08 | -0.09 | -0.09 | -0.11 | -2.92 | 2.69 | 2.68 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -33.33% | 179.55% | -100.00% | 75.00% | -100.00% | -20.00% | 0.00% | -16.67% | -2614.29% | 192.11% |
| Change in YoY Net Profit Growth (%) | 0.00% | 212.88% | -279.55% | 175.00% | -175.00% | 80.00% | 20.00% | -16.67% | -2597.62% | 2806.39% |
Genesis IBRC India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 106% |
| 3 Years: | 215% |
| TTM: | 191% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 40% |
| 3 Years: | 54% |
| 1 Year: | 152% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | -2% |
| Last Year: | 52% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:56 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.02 | 7.12 | 9.74 | 10.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 |
| Reserves | -3.25 | -3.70 | -3.35 | -3.35 | -3.55 | -3.70 | -3.80 | -3.92 | -4.04 | -4.17 | -7.97 | -4.47 | -4.65 |
| Borrowings | 0.61 | 0.17 | 0.20 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Other Liabilities | 0.90 | 0.93 | 0.51 | 0.03 | 0.07 | 0.08 | 0.12 | 0.12 | 0.13 | 0.14 | 0.18 | 0.30 | 0.16 |
| Total Liabilities | 1.28 | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
| Fixed Assets | 1.10 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | 4.66 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Other Assets | 0.18 | 4.52 | 7.10 | 6.68 | 4.86 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
| Total Assets | 1.28 | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
Below is a detailed analysis of the balance sheet data for Genesis IBRC India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is -4.65 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -4.47 Cr. (Mar 2025) to -4.65 Cr., marking a decline of 0.18 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.16 Cr.. The value appears to be improving (decreasing). It has decreased from 0.30 Cr. (Mar 2025) to 0.16 Cr., marking a decrease of 0.14 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8.51 Cr.. The value appears to be improving (decreasing). It has decreased from 8.83 Cr. (Mar 2025) to 8.51 Cr., marking a decrease of 0.32 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 8.51 Cr.. The value appears to be declining and may need further review. It has decreased from 8.83 Cr. (Mar 2025) to 8.51 Cr., marking a decrease of 0.32 Cr..
- For Total Assets, as of Sep 2025, the value is 8.51 Cr.. The value appears to be declining and may need further review. It has decreased from 8.83 Cr. (Mar 2025) to 8.51 Cr., marking a decrease of 0.32 Cr..
However, the Borrowings (0.00 Cr.) are higher than the Reserves (-4.65 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.77 | -0.32 | -0.27 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28.08 | 229.29 | 62.93 | 292.00 | ||||||||
| Inventory Days | 104.29 | 0.00 | 0.00 | |||||||||
| Days Payable | 156.43 | |||||||||||
| Cash Conversion Cycle | -24.07 | 229.29 | 62.93 | 292.00 | ||||||||
| Working Capital Days | -1,272.82 | 1,586.35 | 5,991.03 | 67,890.00 | ||||||||
| ROCE % | -60.55% | -16.62% | 6.88% | 0.00% | -2.48% | -0.53% | -1.08% | -1.31% | -1.33% | -1.57% | -54.83% | 51.62% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 18 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | -0.03 |
| Diluted EPS (Rs.) | -0.03 |
| Cash EPS (Rs.) | 0.04 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 7.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 7.39 |
| Revenue From Operations / Share (Rs.) | 3.33 |
| PBDIT / Share (Rs.) | 0.14 |
| PBIT / Share (Rs.) | 0.06 |
| PBT / Share (Rs.) | 0.04 |
| Net Profit / Share (Rs.) | -0.02 |
| NP After MI And SOA / Share (Rs.) | -0.02 |
| PBDIT Margin (%) | 4.20 |
| PBIT Margin (%) | 2.02 |
| PBT Margin (%) | 1.41 |
| Net Profit Margin (%) | -0.78 |
| NP After MI And SOA Margin (%) | -0.78 |
| Return on Networth / Equity (%) | -0.35 |
| Return on Capital Employeed (%) | 0.87 |
| Return On Assets (%) | -0.27 |
| Current Ratio (X) | 3.24 |
| Quick Ratio (X) | 3.00 |
| Interest Coverage Ratio (X) | 6.83 |
| Interest Coverage Ratio (Post Tax) (X) | -0.27 |
| Enterprise Value (Cr.) | 6.58 |
| EV / Net Operating Revenue (X) | 1.52 |
| EV / EBITDA (X) | 36.12 |
| MarketCap / Net Operating Revenue (X) | 1.59 |
| Price / BV (X) | 0.71 |
| Price / Net Operating Revenue (X) | 1.59 |
After reviewing the key financial ratios for Genesis IBRC India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 18, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 18, the value is -0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 18, the value is -0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 18, the value is 0.04. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 18, the value is 7.39. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 18, the value is 7.39. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 18, the value is 3.33. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 18, the value is 0.14. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 18, the value is 0.06. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 18, the value is 0.04. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 18, the value is -0.02. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 18, the value is -0.02. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 18, the value is 4.20. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 18, the value is 2.02. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 18, the value is 1.41. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 18, the value is -0.78. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 18, the value is -0.78. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 18, the value is -0.35. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 18, the value is 0.87. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 18, the value is -0.27. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 18, the value is 3.24. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 18, the value is 3.00. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 18, the value is 6.83. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 18, the value is -0.27. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 18, the value is 6.58. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 18, the value is 1.52. This value is within the healthy range. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 18, the value is 36.12. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 18, the value is 1.59. This value is within the healthy range. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 18, the value is 0.71. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 18, the value is 1.59. This value is within the healthy range. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genesis IBRC India Ltd:
- Net Profit Margin: -0.78%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.87% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.35% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.27
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 32.19)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.78%
FAQ
What is the intrinsic value of Genesis IBRC India Ltd?
Genesis IBRC India Ltd's intrinsic value (as of 08 December 2025) is 40.55 which is 61.75% lower the current market price of 106.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 137 Cr. market cap, FY2025-2026 high/low of 185/16.6, reserves of ₹-4.65 Cr, and liabilities of 8.51 Cr.
What is the Market Cap of Genesis IBRC India Ltd?
The Market Cap of Genesis IBRC India Ltd is 137 Cr..
What is the current Stock Price of Genesis IBRC India Ltd as on 08 December 2025?
The current stock price of Genesis IBRC India Ltd as on 08 December 2025 is 106.
What is the High / Low of Genesis IBRC India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genesis IBRC India Ltd stocks is 185/16.6.
What is the Stock P/E of Genesis IBRC India Ltd?
The Stock P/E of Genesis IBRC India Ltd is .
What is the Book Value of Genesis IBRC India Ltd?
The Book Value of Genesis IBRC India Ltd is 6.42.
What is the Dividend Yield of Genesis IBRC India Ltd?
The Dividend Yield of Genesis IBRC India Ltd is 0.00 %.
What is the ROCE of Genesis IBRC India Ltd?
The ROCE of Genesis IBRC India Ltd is 51.6 %.
What is the ROE of Genesis IBRC India Ltd?
The ROE of Genesis IBRC India Ltd is 51.6 %.
What is the Face Value of Genesis IBRC India Ltd?
The Face Value of Genesis IBRC India Ltd is 10.0.